Rémy Gébleux

Title: Rémy Gébleux: Innovator in Antibody Technology

Introduction

Rémy Gébleux is a notable inventor based in Olten, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of innovative antibody variants. His work focuses on enhancing the properties of antibodies for improved therapeutic applications.

Latest Patents

One of Rémy Gébleux's key patents is titled "Non-glycosylated anti-tenascin antibody." This invention relates to variants of the anti-tenascin antibody F16, which have been modified to abolish N-glycosylation at positions 88 to 90 in the VL domain. The modifications result in dramatically improved properties, such as enhanced binding affinity and tumor biodistribution in vivo. The patent provides variant F16 antibody molecules along with methods for their production and use.

Career Highlights

Rémy Gébleux is associated with Philogen S.p.a., a company known for its innovative approaches in the field of biopharmaceuticals. His work at Philogen has allowed him to explore and develop cutting-edge technologies that have the potential to revolutionize cancer treatment.

Collaborations

Rémy collaborates with various professionals in the field, including his coworker Sarah Wulhfard. Their combined expertise contributes to the advancement of antibody technology and its applications in medicine.

Conclusion

Rémy Gébleux's contributions to antibody technology exemplify the innovative spirit of modern biotechnology. His work not only enhances our understanding of antibody functionality but also paves the way for new therapeutic strategies.